報價延遲最少15分鐘:2025/01/11 18:01 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
8.46 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-36.00/-10.40
|
|
企業價值
306.67M
|
| 資產負債 |
|
每股賬面淨值
-0.60
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
29.50M
|
|
每股收益
2.23
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/01/11 18:01 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. |